已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract CT010: Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors

医学 克洛丹 抗体-药物偶联物 结合 药品 药理学 癌症研究 抗体 单克隆抗体 化学 紧密连接 免疫学 数学 生物化学 数学分析
作者
Rui-Hua Xu,Dan‐Yun Ruan,Rongbo Lin,Jianzhen Shan,Peng Nie,Yinghua Ji,Jing Wang,Yu Cao,Funan Liu,Jie-Er Ying,Jie Liu,Tao Zhang,Huiting Xu,Yanqiao Zhang,Wen-Can Song,Jing Xia,Wenfeng Li,Zhiye Zhang,Jian Shi,Mingxia Wang
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:85 (8_Supplement_2): CT010-CT010 被引量:1
标识
DOI:10.1158/1538-7445.am2025-ct010
摘要

Abstract Background: JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we report the safety and efficacy results of JS107 monotherapy or in combination for pts with advanced solid tumors from the first-in-human phase 1 trial (NCT05502393). Methods: In Part A of the study, pts with advanced solid tumors refractory to standard therapies were treated with JS107 at 0.15-3.5 mg/kg Q3W during dose escalation and CLDN18.2+ pts were treated with JS107 at 2.0 and 3.0 mg/kg Q3W during dose expansion. In Part B of the study, pts with CLDN18.2+, HER2-negative, previously untreated, advanced gastric or gastroesophageal junction cancer (GC/GEJ) were treated with JS107 combined with toripalimab (240 mg Q3W) and XELOX (capecitabine and oxaliplatin), in dose escalation (JS107 at 2.0-3.0 mg/kg Q3W) and expansion (JS107 at 2.0 mg/kg Q3W) phases. The primary endpoint was safety. Secondary endpoints included efficacy and pharmacokinetics (PK). Results: As of January 7, 2025, 63 pts were enrolled in Part A (22 in dose escalation and 41 in dose expansion) and 27 enrolled in Part B (9 in dose escalation and 18 in dose expansion). The maximum tolerated dose was not reached for JS107 monotherapy and was 2.5 mg/kg for combination treatment. Grade 3 and above treatment-related adverse events (TRAEs) occurred in 47.6% pts in Part A and 40.7% pts in Part B. The most frequent grade 3 and above TRAE was neutropenia (22.2%) in Part A and thrombocytopenia (18.5%) in Part B. Among pts with CLDN18.2-high (defined as ≥20% of tumor cells with ≥2+ staining intensity) GC/GEJ who received JS107 monotherapy at 2.0-3.0 mg/kg (n=24), the objective response rate (ORR) was 34.8% (8/23, 95%CI 16.4-57.3) and median progression-free survival was 4.11 months (95%CI 3.15-9.63). Among efficacy evaluable pts with CLDN18.2-high GC/GEJ in Part B (n=14), the ORR was 78.6% (11/14, 95%CI 49.2-95.3). A positive association between CLDN18.2 expression level and efficacy was observed in Part A and Part B. PK analysis showed a dose-dependent ADC and total antibody exposure at doses of 0.15-3.5 mg/kg. JS107 elimination half-life was 4.41-6.96 days at doses of 2.0-3.5 mg/kg, with no obvious accumulation observed after multiple dosing. Conclusions: JS107 monotherapy or in combination with toripalimab and XELOX showed promising efficacy in pts with CLDN18.2-high advanced GC/GEJ with a manageable safety profile. The clinical benefit of CLDN18.2 ADC combination treatment was thus demonstrated for the first time. Further clinical development of JS107 in CLDN18.2+ advanced solid tumors is warranted. Citation Format: Rui-Hua Xu, Dan-Yun Ruan, Rong-Bo Lin, Jian-Zhen Shan, Peng Nie, Ying-Hua Ji, Jing Wang, Yu Cao, Fu-Nan Liu, Jie-Er Ying, Li Liu, Tao Zhang, Hui-Ting Xu, Yan-Qiao Zhang, Wen-Can Song, Jin Xia, Wen-Feng Li, Zhi-Ye Zhang, Jian Shi, Ming-Xia Wang, Long Wu, Yan-Yan Lu, Xiao Zhang, Yan-Yan Hu, Yong-Dong Zhang. Phase I dose-escalation and expansion study of JS107, a claudin 18.2 (CLDN18.2)-targeting antibody-drug conjugate (ADC), as monotherapy or in combination for patients (pts) with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT010.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
天天快乐的应助被Shonso采纳,获得30
刚刚
刚刚
刚刚
小马甲的应助被dochz采纳,获得10
刚刚
1秒前
结实初翠完成签到,获得积分10
1秒前
1秒前
结实初翠发布了新的文献求助10
4秒前
dake发布了新的社区帖子
4秒前
石永怡发布了新的文献求助20
6秒前
hyman发布了新的文献求助10
6秒前
6秒前
yyy完成签到 ,获得积分10
6秒前
甜蜜邑完成签到 ,获得积分10
6秒前
赖茜发布了新的文献求助10
7秒前
answer答案完成签到,获得积分10
9秒前
11秒前
隐形曼青的应助被墨苒采纳,获得10
13秒前
知云完成签到 ,获得积分10
14秒前
某某完成签到 ,获得积分10
14秒前
GingerF的应助被科研通管家采纳,获得60
15秒前
顾矜的应助被科研通管家采纳,获得10
15秒前
天天快乐的应助被科研通管家采纳,获得10
15秒前
15秒前
molihuakai的应助被科研通管家采纳,获得10
15秒前
星辰大海的应助被科研通管家采纳,获得10
15秒前
15秒前
15秒前
华仔的应助被科研通管家采纳,获得10
16秒前
在水一方的应助被科研通管家采纳,获得10
16秒前
16秒前
Nole的应助被科研通管家采纳,获得30
16秒前
Jasper的应助被科研通管家采纳,获得10
16秒前
情怀的应助被科研通管家采纳,获得10
16秒前
Lucas的应助被科研通管家采纳,获得10
16秒前
Nole的应助被科研通管家采纳,获得30
16秒前
幸福完成签到 ,获得积分10
17秒前
18秒前
19秒前
微山发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184723
求助须知:如何正确求助?哪些是违规求助? 9573702
关于积分的说明 21832740
捐赠科研通 7782090
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481054